Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
PAR Technology Corporation stock logo
PAR
PAR Technology
$69.08
-0.8%
$66.02
$43.50
$82.24
$2.80B1.69433,290 shs296,998 shs
Pfenex Inc. stock logo
PFNX
Pfenex
$12.75
$12.75
$5.26
$14.00
$437.29MN/A503,865 shsN/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
C$0.00
C$7.13
C$590.00
C$317.06MN/A8,002 shs921 shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$15.97
-0.8%
$16.73
$13.61
$30.36
$5.40BN/A29,159 shs31,666 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
PAR Technology Corporation stock logo
PAR
PAR Technology
+0.32%+0.16%+5.31%+26.53%+51.70%
Pfenex Inc. stock logo
PFNX
Pfenex
0.00%0.00%0.00%0.00%0.00%
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
0.00%0.00%0.00%0.00%0.00%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-4.85%-0.15%-6.77%-3.30%+1,609,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
PAR Technology Corporation stock logo
PAR
PAR Technology
0.9163 of 5 stars
2.41.00.00.00.00.80.6
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
PAR Technology Corporation stock logo
PAR
PAR Technology
2.75
Moderate Buy$79.8615.60% Upside
Pfenex Inc. stock logo
PFNX
Pfenex
0.00
N/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
0.00
N/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
3.00
Buy$22.3339.85% Upside

Current Analyst Ratings Breakdown

Latest PFNX, TLX, SPL, PLI, and PAR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
PAR Technology Corporation stock logo
PAR
PAR Technology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00
7/9/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
7/3/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$23.00
6/12/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$22.00
6/5/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$22.00
5/12/2025
PAR Technology Corporation stock logo
PAR
PAR Technology
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$57.00 ➝ $65.00
5/12/2025
PAR Technology Corporation stock logo
PAR
PAR Technology
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00 ➝ $90.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
PAR Technology Corporation stock logo
PAR
PAR Technology
$383.77M7.29N/AN/A$22.51 per share3.07
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
C$39.91M0.00N/A3.94C$6.07 per share0.00
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$516.72M10.46$0.11 per share148.17$1.12 per share14.26
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
PAR Technology Corporation stock logo
PAR
PAR Technology
-$4.99M-$0.13N/AN/AN/A-2.88%-3.90%-2.29%8/6/2025 (Estimated)
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/A0.00N/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
N/A-C$63.06N/AN/AN/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$32.93MN/A0.0033.27N/AN/AN/AN/AN/A

Latest PFNX, TLX, SPL, PLI, and PAR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2025Q1 2025
PAR Technology Corporation stock logo
PAR
PAR Technology
-$0.05-$0.01+$0.04-$0.60$105.16 million$103.86 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
PAR Technology Corporation stock logo
PAR
PAR Technology
$0.310.45%N/AN/A N/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
PAR Technology Corporation stock logo
PAR
PAR Technology
0.46
2.05
1.83
Pfenex Inc. stock logo
PFNX
Pfenex
N/AN/AN/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
37.47
4.06
3.66
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.99
2.78
2.66

Institutional Ownership

CompanyInstitutional Ownership
PAR Technology Corporation stock logo
PAR
PAR Technology
N/A
Pfenex Inc. stock logo
PFNX
Pfenex
N/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
N/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
PAR Technology Corporation stock logo
PAR
PAR Technology
3.70%
Pfenex Inc. stock logo
PFNX
Pfenex
N/A
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
N/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
PAR Technology Corporation stock logo
PAR
PAR Technology
1,58540.50 million39.00 millionOptionable
Pfenex Inc. stock logo
PFNX
Pfenex
7134.30 millionN/ANot Optionable
ProMetic Life Sciences Inc. stock logo
PLI
ProMetic Life Sciences
48723.31 millionN/ANot Optionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A338.38 millionN/AN/A

Recent News About These Companies

Gozellix Receives Permanent HCPCS Code
Telix shares jump 7% on big US news

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
PAR Technology stock logo

PAR Technology NYSE:PAR

$69.08 -0.53 (-0.76%)
Closing price 03:58 PM Eastern
Extended Trading
$69.10 +0.02 (+0.03%)
As of 04:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PAR Technology Corporation, together with its subsidiaries, provides omnichannel cloud-based hardware and software solutions to the restaurant and retail industries worldwide. The Restaurant/Retail segment offers PUNCHH, an enterprise-grade customer loyalty and engagement solution; MENU, an eCommerce platform for restaurant brands; BRINK POS, an open cloud, point-of-sale solution; PAR PAYMENT SERVICES, a merchant services business that enables electronic payment and processing services for businesses; and DATA CENTRAL, a back-office solution that leverages business intelligence and automation technologies. This segment also offers Point-of-Sale Hardware; wireless headsets for drive-thru order-taking; and kitchen display systems, payment devices, cash drawers, printers, and other peripherals. In addition, this segment provides services, such as hardware repair, installation and implementation, training, and on-site and technical support services. The Government segment provides intelligence, surveillance, and reconnaissance solutions; mission systems operations and maintenance, and commercial software products; systems engineering support and software-based solutions; satellite and teleport facility operation and maintenance, engineering, and installation services comprising inside and outside plant services, and maintenance of infrastructure and information systems; satellite ground system support comprising operations and maintenance, sustainment, upgrades, communications security management, anomaly response/resolution, process improvement, emergency response, and disaster recovery services; and information technology infrastructure library services to the United States Department of Defense, intelligence community (IC), and other federal agencies. This segment also offers various IC support services, systems integration, situational awareness solutions, and mission readiness support services. The company was founded in 1968 and is based in New Hartford, New York.

Pfenex stock logo

Pfenex NYSEAMERICAN:PFNX

$12.75 0.00 (0.00%)
As of 10/1/2020

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

ProMetic Life Sciences stock logo

ProMetic Life Sciences TSE:PLI

Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$15.97 -0.13 (-0.81%)
Closing price 04:00 PM Eastern
Extended Trading
$15.93 -0.04 (-0.25%)
As of 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.